Hennion & Walsh Asset Management Inc. increased its stake in shares of Zai Lab Limited (NASDAQ:ZLAB – Free Report) by 35.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 63,169 shares of the company’s stock after buying an additional 16,659 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.06% of Zai Lab worth $1,012,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the stock. Allianz Asset Management GmbH lifted its holdings in Zai Lab by 26.1% during the fourth quarter. Allianz Asset Management GmbH now owns 679,524 shares of the company’s stock valued at $18,571,000 after purchasing an additional 140,461 shares during the last quarter. Baader Bank Aktiengesellschaft purchased a new stake in shares of Zai Lab during the 4th quarter valued at approximately $253,000. China Universal Asset Management Co. Ltd. boosted its holdings in Zai Lab by 323.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,802 shares of the company’s stock worth $159,000 after buying an additional 4,431 shares during the period. Wellington Management Group LLP grew its stake in Zai Lab by 177.6% in the 4th quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company’s stock valued at $145,845,000 after buying an additional 3,413,829 shares in the last quarter. Finally, Bellevue Group AG bought a new stake in Zai Lab during the 4th quarter valued at $3,714,000. Institutional investors own 41.65% of the company’s stock.
Zai Lab Stock Performance
ZLAB opened at $17.29 on Tuesday. Zai Lab Limited has a one year low of $13.48 and a one year high of $32.60. The company has a fifty day moving average price of $18.41 and a 200-day moving average price of $19.98.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research note on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $64.57.
Get Our Latest Stock Analysis on ZLAB
Insider Activity at Zai Lab
In other news, insider Joshua L. Smiley sold 1,988 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total value of $31,151.96. Following the transaction, the insider now owns 28,684 shares of the company’s stock, valued at approximately $449,478.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Zai Lab news, insider Harald Reinhart sold 7,431 shares of the stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total transaction of $133,014.90. Following the transaction, the insider now directly owns 62,619 shares in the company, valued at $1,120,880.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joshua L. Smiley sold 1,988 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the completion of the sale, the insider now owns 28,684 shares of the company’s stock, valued at $449,478.28. The disclosure for this sale can be found here. Insiders have sold 46,357 shares of company stock valued at $857,773 over the last three months. 5.23% of the stock is owned by corporate insiders.
Zai Lab Company Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Further Reading
- Five stocks we like better than Zai Lab
- Why Invest in 5G? How to Invest in 5G Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Investors Need to Know About Upcoming IPOs
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Use Stock Screeners to Find Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Limited (NASDAQ:ZLAB – Free Report).
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.